Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Breast Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    November 2020
  1. XU Y, Liao S, Wang L, Wang Y, et al
    Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and beta-catenin.
    Cancer Chemother Pharmacol. 2020 Nov 7. pii: 10.1007/s00280-020-04195.
    PubMed     Abstract available


    October 2020
  2. TSUJI D, Matsumoto M, Kawasaki Y, Kim YL, et al
    Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
    Cancer Chemother Pharmacol. 2020 Oct 24. pii: 10.1007/s00280-020-04177.
    PubMed     Abstract available


  3. ZHANG Z, Zhang L, Yu G, Sun Z, et al
    Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2020 Oct 17. pii: 10.1007/s00280-020-04168.
    PubMed     Abstract available


    June 2020
  4. TSUKIOKI T, Shien T, Tanaka T, Suzuki Y, et al
    Influences of preoperative metformin on immunological factors in early breast cancer.
    Cancer Chemother Pharmacol. 2020 Jun 12. pii: 10.1007/s00280-020-04092.
    PubMed     Abstract available


    May 2020
  5. SANCHEZ-SPITMAN AB, Moes DAR, Swen JJ, Dezentje VO, et al
    Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
    Cancer Chemother Pharmacol. 2020 May 29. pii: 10.1007/s00280-020-04089.
    PubMed     Abstract available


    April 2020
  6. YANG H, Lu Y, Zheng Y, Yu X, et al
    Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells.
    Cancer Chemother Pharmacol. 2020 Apr 10. pii: 10.1007/s00280-020-04044.
    PubMed    


  7. TOLCHER AW, Kurzrock R, Valero V, Gonzalez R, et al
    Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.
    Cancer Chemother Pharmacol. 2020;85:673-683.
    PubMed     Abstract available


    March 2020
  8. MORTIMER JE, Kruper L, Jung J, Wong L, et al
    Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab.
    Cancer Chemother Pharmacol. 2020;85:501-507.
    PubMed     Abstract available


    February 2020
  9. POTHURI B, Brodsky AL, Sparano JA, Blank SV, et al
    Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    Cancer Chemother Pharmacol. 2020 Feb 13. pii: 10.1007/s00280-020-04030.
    PubMed     Abstract available


  10. TONRA JR, Lloyd GK, Mohanlal R, Huang L, et al
    Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.
    Cancer Chemother Pharmacol. 2020;85:461-468.
    PubMed     Abstract available


    January 2020
  11. LIANG Z, Feng A, Shim H
    MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer.
    Cancer Chemother Pharmacol. 2020 Jan 6. pii: 10.1007/s00280-019-04024.
    PubMed     Abstract available


    December 2019
  12. PATTARAWAT P, Wallace S, Pfisterer B, Odoi A, et al
    Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Cancer Chemother Pharmacol. 2019 Dec 21. pii: 10.1007/s00280-019-04013.
    PubMed     Abstract available


  13. ZHAO Y, Wei L, Liu J, Li F, et al
    Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer.
    Cancer Chemother Pharmacol. 2019 Dec 16. pii: 10.1007/s00280-019-04009.
    PubMed     Abstract available


  14. HUANG L, Wang X, Zhou L, Di L, et al
    Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Dec 14. pii: 10.1007/s00280-019-04000.
    PubMed     Abstract available


    November 2019
  15. ROSSI L, Verrico M, Tomao S, Ricci F, et al
    Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2019 Nov 21. pii: 10.1007/s00280-019-03981.
    PubMed     Abstract available


  16. XU Z, Luo F, Wang Y, Zou BS, et al
    Cognitive impairments in breast cancer survivors treated with chemotherapy: a study based on event-related potentials.
    Cancer Chemother Pharmacol. 2019 Nov 19. pii: 10.1007/s00280-019-03994.
    PubMed     Abstract available


    October 2019
  17. SENTURK M, Ercan F, Yalcin S
    The secondary metabolites produced by Lactobacillus plantarum downregulate BCL-2 and BUFFY genes on breast cancer cell line and model organism Drosophila melanogaster: molecular docking approach.
    Cancer Chemother Pharmacol. 2019 Oct 31. pii: 10.1007/s00280-019-03978.
    PubMed     Abstract available


    September 2019
  18. SUN Y, Lin X, Aske JC, Ye P, et al
    Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2019 Sep 20. pii: 10.1007/s00280-019-03962.
    PubMed     Abstract available


  19. CRUCITTA S, Restante G, Del Re M, Bertolini I, et al
    Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.
    Cancer Chemother Pharmacol. 2019 Sep 16. pii: 10.1007/s00280-019-03933.
    PubMed     Abstract available


  20. SUN Y, Yan L, Guo J, Shao J, et al
    Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.
    Cancer Chemother Pharmacol. 2019 Sep 12. pii: 10.1007/s00280-019-03945.
    PubMed     Abstract available


  21. SAKURADA T, Bando S, Zamami Y, Takechi K, et al
    Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Cancer Chemother Pharmacol. 2019 Sep 9. pii: 10.1007/s00280-019-03948.
    PubMed     Abstract available


  22. LIU B, Su F, Lv X, Zhang W, et al
    Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
    Cancer Chemother Pharmacol. 2019 Sep 4. pii: 10.1007/s00280-019-03937.
    PubMed     Abstract available


    August 2019
  23. NUTHALAPATI S, Stodtmann S, Shepherd SP, Ratajczak CK, et al
    Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
    Cancer Chemother Pharmacol. 2019 Aug 29. pii: 10.1007/s00280-019-03930.
    PubMed     Abstract available


  24. ESTEVA FJ, Baranau YV, Baryash V, Manikhas A, et al
    Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
    Cancer Chemother Pharmacol. 2019 Aug 19. pii: 10.1007/s00280-019-03920.
    PubMed     Abstract available


  25. XING M, Wang J, Yang Q, Wang Y, et al
    FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
    Cancer Chemother Pharmacol. 2019 Aug 19. pii: 10.1007/s00280-019-03923.
    PubMed     Abstract available


  26. MENG L, Huang L, Xu Y, Zhang W, et al
    Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
    Cancer Chemother Pharmacol. 2019 Aug 3. pii: 10.1007/s00280-019-03909.
    PubMed     Abstract available


    July 2019
  27. PEER CJ, Schmidt KT, Kindrick JD, Eisner JR, et al
    A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 31. pii: 10.1007/s00280-019-03908.
    PubMed     Abstract available


  28. FRAGUAS-SANCHEZ AI, Martin-Sabroso C, Fernandez-Carballido A, Torres-Suarez AI, et al
    Current status of nanomedicine in the chemotherapy of breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 31. pii: 10.1007/s00280-019-03910.
    PubMed     Abstract available


  29. CAO L, Xiang G, Liu F, Xu C, et al
    A high AR:ERalpha or PDEF:ERalpha ratio predicts a sub-optimal response to tamoxifen therapy in ERalpha-positive breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 11. pii: 10.1007/s00280-019-03891.
    PubMed     Abstract available


  30. CHEN X, Li C, Ewesuedo R, Yin D, et al
    Correction to: Population pharmacokinetics of PF05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin((R))) in patients with HER2positive metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jul 10. pii: 10.1007/s00280-019-03890.
    PubMed     Abstract available


    June 2019
  31. KOTAKE M, Imai H, Kaira K, Fujisawa T, et al
    Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.
    Cancer Chemother Pharmacol. 2019 Jun 27. pii: 10.1007/s00280-019-03897.
    PubMed     Abstract available


    May 2019
  32. LU D, Li C, Riggs M, Polhamus D, et al
    Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 May 17. pii: 10.1007/s00280-019-03852.
    PubMed     Abstract available


  33. CHEN X, Li C, Ewesuedo R, Yin D, et al
    Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin((R))) in patients with HER2-positive metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 May 3. pii: 10.1007/s00280-019-03850.
    PubMed     Abstract available


    April 2019
  34. KIRSCHBROWN WP, Kagedal M, Wang B, Lindbom L, et al
    Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
    Cancer Chemother Pharmacol. 2019 Apr 11. pii: 10.1007/s00280-019-03826.
    PubMed     Abstract available


  35. ARAZ M, Karaagac M, Korkmaz L, Koral L, et al
    Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
    Cancer Chemother Pharmacol. 2019 Apr 8. pii: 10.1007/s00280-019-03831.
    PubMed     Abstract available


  36. TANAKA S, Matsunami N, Morishima H, Oda N, et al
    De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Cancer Chemother Pharmacol. 2019 Apr 8. pii: 10.1007/s00280-019-03836.
    PubMed     Abstract available


    January 2019
  37. CAMPONE M, Bachelot T, Penault-Llorca F, Pallis A, et al
    A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
    Cancer Chemother Pharmacol. 2019 Jan 25. pii: 10.1007/s00280-018-03765.
    PubMed     Abstract available


  38. NGUYEN TT, Angeli E, Darrouzain F, Nguyen QT, et al
    A successful compartmental approach for the treatment of breast cancer brain metastases.
    Cancer Chemother Pharmacol. 2019 Jan 5. pii: 10.1007/s00280-018-3752.
    PubMed     Abstract available


    November 2018
  39. CAZZANIGA ME, Ciruelos E, Fabi A, Garcia-Saenz J, et al
    Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project.
    Cancer Chemother Pharmacol. 2018 Nov 20. pii: 10.1007/s00280-018-3717.
    PubMed     Abstract available


    October 2018
  40. ESIN E, Oksuzoglu B, Bilici A, Cicin I, et al
    Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes.
    Cancer Chemother Pharmacol. 2018 Oct 30. pii: 10.1007/s00280-018-3712.
    PubMed     Abstract available


  41. BAI Y, Wu HW, Zhang YH
    Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
    Cancer Chemother Pharmacol. 2018 Oct 24. pii: 10.1007/s00280-018-3703.
    PubMed     Abstract available


    July 2018
  42. HUANG W, Liu J, Zeng Y, Wu F, et al
    Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Cancer Chemother Pharmacol. 2018 Jul 24. pii: 10.1007/s00280-018-3639.
    PubMed     Abstract available


    June 2018
  43. XU C, Ravva P, Dang JS, Laurent J, et al
    A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
    Cancer Chemother Pharmacol. 2018 Jun 18. pii: 10.1007/s00280-018-3621.
    PubMed     Abstract available


  44. RODON J, Perez-Fidalgo A, Krop IE, Burris H, et al
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2018 Jun 7. pii: 10.1007/s00280-018-3610.
    PubMed     Abstract available


  45. IIZUMI S, Shimomura A, Shimoi T, Sudo K, et al
    Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.
    Cancer Chemother Pharmacol. 2018 Jun 5. pii: 10.1007/s00280-018-3617.
    PubMed     Abstract available


    May 2018
  46. HUANG JF, Wen CJ, Zhao GZ, Dai Y, et al
    Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3603.
    PubMed     Abstract available


  47. LEUNG HW, Ko CH, Yue GG, Herr I, et al
    The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells.
    Cancer Chemother Pharmacol. 2018 May 18. pii: 10.1007/s00280-018-3601.
    PubMed     Abstract available


  48. LITVIAKOV N, Tsyganov M, Larionova I, Ibragimova M, et al
    Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3594.
    PubMed     Abstract available


    March 2018
  49. KIMURA K, Iwamoto M, Tanaka S, Yamamoto D, et al
    A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
    Cancer Chemother Pharmacol. 2018 Mar 28. pii: 10.1007/s00280-018-3567.
    PubMed     Abstract available


    February 2018
  50. CITI V, Del Re M, Martelli A, Calderone V, et al
    Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
    Cancer Chemother Pharmacol. 2018 Feb 23. pii: 10.1007/s00280-018-3543.
    PubMed     Abstract available


  51. NAKAYAMA T, Sagara Y, Takashima T, Matsunami N, et al
    Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
    Cancer Chemother Pharmacol. 2018 Feb 21. pii: 10.1007/s00280-018-3544.
    PubMed     Abstract available


  52. LIU Z, Tao Z, Zhang Q, Wan S, et al
    YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 1. pii: 10.1007/s00280-018-3535.
    PubMed     Abstract available


    December 2017
  53. ZHOU X, Qiao G, Wang X, Song Q, et al
    CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
    Cancer Chemother Pharmacol. 2017 Dec 14. pii: 10.1007/s00280-017-3500.
    PubMed     Abstract available


  54. SHIEN T, Doihara H, Sato N, Anan K, et al
    Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
    Cancer Chemother Pharmacol. 2017 Dec 1. pii: 10.1007/s00280-017-3491.
    PubMed     Abstract available


    October 2017
  55. LI C, Wang B, Chen SC, Wada R, et al
    Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Cancer Chemother Pharmacol. 2017 Oct 11. doi: 10.1007/s00280-017-3440.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: